ZACHARY ROBINSON: Open Payments
NPI 1942934179 · PEARL, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,137 in 51 payments from 11 companies in 2025. Trend: 2023 $1,023 · 2024 $1,468 · 2025 $1,137
Food & beverage: $1,137
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 15 | $301 |
| Alkermes, Inc. | 10 | $209 |
| Neurocrine BioSciences, Inc. | 6 | $128 |
| Janssen Pharmaceuticals, Inc | 5 | $126 |
| Vanda Pharmaceuticals Inc. | 2 | $101 |
| Teva Pharmaceuticals USA, Inc. | 4 | $80 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
| ABBVIE INC. | 2 | $49 |
| Lundbeck LLC | 2 | $45 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
Products named: COBENFY, ARISTADA, INGREZZA, INVEGA SUSTENNA, FANAPT, LYBALVI, REXULTI, UZEDY.
Industry payments across MS — which companies pay providers there.
